Ocular Therapeutix (OCUL) Debt to Equity (2016 - 2025)
Ocular Therapeutix (OCUL) has 13 years of Debt to Equity data on record, last reported at $0.11 in Q4 2025.
- For Q4 2025, Debt to Equity fell 49.81% year-over-year to $0.11; the TTM value through Dec 2025 reached $0.11, down 49.81%, while the annual FY2025 figure was $0.11, 49.81% down from the prior year.
- Debt to Equity reached $0.11 in Q4 2025 per OCUL's latest filing, down from $0.27 in the prior quarter.
- Across five years, Debt to Equity topped out at $8.29 in Q3 2023 and bottomed at $0.11 in Q4 2025.
- Average Debt to Equity over 5 years is $1.19, with a median of $0.28 recorded in 2021.
- Peak YoY movement for Debt to Equity: skyrocketed 1876.8% in 2023, then crashed 97.68% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.28 in 2021, then skyrocketed by 151.29% to $0.71 in 2022, then increased by 1.12% to $0.72 in 2023, then crashed by 69.91% to $0.22 in 2024, then tumbled by 49.81% to $0.11 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.11 in Q4 2025, $0.27 in Q3 2025, and $0.23 in Q2 2025.